Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants.
Explore this paper's citation graph
Summary
Cytogenetics play a dominant role in myeloma and were independent of previously recognized important prognostic factors, such as B2M and duration of prior standard therapy.
- Type
- article
- Published
- 1997-07-01
- Cited by
- 190
- References
- 40
- OpenAlex
- https://openalex.org/W1918030391
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:10813943
Keywords
Medicine, Cytogenetics, Multiple myeloma, Internal medicine, Oncology
References
- Deletion of the retinoblastoma gene in multiple myeloma.
- Ploidy and proliferative characteristics in monoclonal gammopathies.
- p53 and RAS gene mutations in multiple myeloma.
- Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis.
- Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias.
- Graft-versus-myeloma effect: proof of principle.
- p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias.
- Mutations of the p53 gene in human myeloma cell lines.
- Incidence of chromosome numerical changes in multiple myeloma: fluorescence in situ hybridization analysis using 15 chromosome-specific probes.
- Autotransplants in multiple myeloma: what have we learned?
- The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis.
- The growth fraction of human myeloma cells.
- Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines.
- Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
- Impact of chromosomal translocations on prognosis in childhood acute lymphoblastic leukemia.
- p53 abnormalities and genomic instability in primary human breast carcinomas.
- Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities.
- Karyotype in multiple myeloma and plasma cell leukaemia.
- Graft-versus-myeloma effect in two cases.
- p53, guardian of the genome
Cited by
- Cyclin D1 and E2F‐1 immunoreactivity in bone marrow biopsy specimens of multiple myeloma: relationship to proliferative activity, cytogenetic abnormalities and DNA ploidy
- Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy
- Risk stratification of patients with newly diagnosed multiple myeloma: optimizing treatment based on pretreatment characteristics.
- Multiple myeloma
- Prognosis in multiple myeloma.
- High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH.
- Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping.
- Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies.
- New questions about transplantation in multiple myeloma.
- Progress in myeloma stem cells.
- Novel cytokines in growth control and bone disease of multiple myeloma
- Diagnostic and Therapeutic Advances in Hematologic Malignancies
- An update on molecular biology and drug resistance mechanisms of multiple myeloma.
- Multiple myeloma: is it time for biomarker-driven therapy?
- Cure of multiple myeloma – more hype, less reality
- Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin.
- Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization.
- New Genetic Insights and Therapy in Multiple Myeloma
- Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study.
- Predictive role of interphase cytogenetics for survival of patients with multiple myeloma.
Related papers
- Cytogenetic studies in patients with multiple myeloma.
- Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients
- P61. Identification of serum lactate dehydrogenase (LDH) as a significant prognostic variable for survival: Multivariate analysis in women with metastatic breast cancer (BC)
- Analyzing the Prognostic Factors of Multiple Myeloma
- [Prognostic factors and risk groupings in multiple myeloma].
- Prognostic flow cytometric information in cervical squamous cell carcinoma: A multivariate analysis of 307 patients
- Prediction of Prognosis in Patients with Gastric Cancer by Quantitative Morphology and Multivariate Analysis
- First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations